

META HEALTH LIMITED

(Incorporated in the Republic of Singapore)

(Company Registration No. 198804700N)

PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 518,066,109 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT A RIGHTS ISSUE PRICE OF S\$0.0055 FOR EACH RIGHTS SHARE ON THE BASIS OF NINE (9) RIGHTS SHARES FOR EVERY TEN (10) EXISTING ORDINARY SHARES IN THE CAPITAL OF THE COMPANY HELD BY EACH SHAREHOLDER OF THE COMPANY AS AT THE RECORD DATE, FRACTIONAL ENTITLEMENTS TO BE DISREGARDED

- RECEIPT OF LISTING AND QUOTATION NOTICE

1. INTRODUCTION

- 1.1. The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”) refers to the Company’s announcements dated 8 August 2023 and 11 September 2023 (the “**Previous Announcements**”) in relation to the Rights Issue.
- 1.2. Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Previous Announcements.

2. RECEIPT OF LISTING AND QUOTATION NOTICE

- 2.1. The Board is pleased to announce that the Company has on 11 September 2023 received the listing and quotation notice from the SGX-ST for the dealing in, listing of and quotation for, up to 518,066,109 Rights Shares on the Catalist board of the SGX-ST (the “**LQN**”). The LQN is subject to the Company’s compliance with the SGX-ST’s listing requirements.
- 2.2. The LQN is not to be taken as an indication of the merits of the Rights Issue, the Rights Shares, the Company and/or its subsidiaries.

3. CAUTIONARY STATEMENT

Shareholders and potential investors are advised to exercise caution when dealing or trading in the Shares. As at the date of this announcement, there is no certainty or assurance that the Rights Issue will be completed or that no changes will be made to the terms thereof. The Company will make the necessary announcements when there are further developments. Shareholders and potential investors are advised to read this announcement, the Previous Announcements and any further announcements by the Company carefully. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers if they have any doubt about the actions they should take.

BY ORDER OF THE BOARD

Lee Wei Hsiung
Company Secretary
12 September 2023

*This announcement has been prepared by Meta Health Limited (the “**Company**”) and its contents have been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (the “**Sponsor**”), in accordance with*

Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalyst.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.